Alto Neuroscience, Inc. (ANRO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $34.89. The rating moved from Neutral to Overbought on August 18, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$34.89
• Last changeMoved from Neutral to Overbought on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Alto Neuroscience, Inc. (ANRO) is a clinical-stage, biomarker-focused CNS company whose valuation is driven largely by upcoming data readouts and the success of its precision-psychiatry approach. The company benefits from a differentiated biomarker strategy that can increase trial efficiency and make it an attractive partner or acquisition target, especially in a market environment where biotech M&A multiples remain elevated. Near-term prospects hinge on clinical validation, cash runway management, and execution on partnerships; absent disruptive trial results or financing developments, expect limited directional movement and event-driven volatility.

Key factors

• Clinical-stage pipeline focused on precision psychiatry with potential to address high-unmet-need CNS disorders
• Proprietary biomarker-driven patient selection approach could improve trial success rates and commercial differentiation
• Limited current revenue; value primarily tied to clinical data readouts and partnering/M&A prospects
• Favorable biotech M&A backdrop and elevated buyer multiples that could support strategic interest or takeout value
• Clean macro environment in the short window observed, with steady market liquidity and selective growth interest
• Management execution and cash runway (funding cadence and burn) will be critical near-term drivers

Risks

• Clinical trial failure or negative biomarker validation undermining the precision-medicine thesis
• High cash burn and need for dilutive financings if partnerships or milestones do not materialize
• Regulatory uncertainty for novel CNS endpoints and biomarker-driven approvals
• Competition from larger biotech/pharma with deeper resources and alternative therapeutic approaches
• Limited public/analyst coverage and sparse social sentiment data increasing volatility on news or filings
• Potential timing risk: meaningful value inflection points depend on specific data release dates and partnering activity

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.